CRISPR Therapeutics AG (CRSP) stock
Close on Nov 12, 2026Market cap $4.12BP/E –Yield –
CRISPR Therapeutics AG saw revenue fall 34.3% to $25.17M over the twelve months to Sep 30, 2026. Free cash flow was -$376.72M. At the latest close the market valued the company at $4.12B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.12B
- P/E ratio
- –
- Price to sales
- 163.72
- Price to book
- 2.50
- Dividend yield
- –
- Free cash flow yield
- -9.14%
Fundamentals
- Revenue
- $25.17M
- Net income
- -$456.14M
- EPS, diluted
- -$4.74
- Free cash flow
- -$376.72M
- Book value per share
- $17.04
- Diluted shares
- 97M
Trading
- Next earnings
- Feb 11, 2027 (estimated, after the close)
- Previous close
- $45.75
- Open
- $45.09
- Day's range
- $42.38 – $45.09
- Volume
- 2,493,021
- Average volume (20 days)
- 1,602,938
- Beta (5 years)
- 1.38
- 52-week range
- $42.38 – $63.45
- RSI (14 days)
- 32.5
- Volatility (1 year)
- 58.4%
- Relative volume
- 1.57×
- WACC
- 11.8%
On 2 of our idea lists: More cash than they're worth, Most shorted (a warning list)
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRSP | S&P 500 | Difference | CRSP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.3% | -2.7% | −14.6 pts | ||
| 3 months | -21.1% | -1.7% | −19.3 pts | ||
| Year to date | -18.7% | +11.9% | −30.6 pts | ||
| 1 year | -18.3% | +12.0% | −30.3 pts | ||
| 3 years | -19.8% | +78.2% | −98.0 pts | -7.1% | +21.2% |
| 5 years | -52.1% | +73.2% | −125.3 pts | -13.7% | +11.6% |
| 10 years | +143.5% | +309.6% | −166.1 pts | +9.3% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CRISPR Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
About CRISPR Therapeutics
Biological Products, (No Diagnostic Substances)
The company is a biopharmaceutical firm that develops gene-based medicines using CRISPR/Cas9 gene-editing technology. It operates across four primary areas: hemoglobinopathies, in vivo editing, CAR T cell therapies, and regenerative medicine. Its approved therapy, CASGEVY, co-developed with Vertex Pharmaceuticals, treats severe sickle cell disease and transfusion-dependent beta thalassemia. Other investigational candidates address cardiovascular conditions, autoimmune disorders, cancers, and Type 1 diabetes. Its end users are patients suffering from severe genetic, hematologic, oncologic, and metabolic diseases.
Company profile, executives and historyCRISPR Therapeutics stock: common questions
What is CRISPR Therapeutics's stock price?
CRSP closed at $42.62 on Nov 12, 2026, down 6.84% on the day. Over the past 52 weeks it traded between $42.38 and $63.45.
What is CRISPR Therapeutics's market cap?
CRISPR Therapeutics was worth $4.12B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CRSP's P/E ratio?
CRISPR Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.74), so it has no meaningful P/E ratio.
How much revenue does CRISPR Therapeutics make?
CRISPR Therapeutics reported revenue of $25.17M for the twelve months to Sep 30, 2026, down 34.3% from a year earlier.
Does CRISPR Therapeutics pay a dividend?
No. CRISPR Therapeutics has not paid a cash dividend over the last twelve months.
When does CRISPR Therapeutics report earnings next?
CRISPR Therapeutics is expected to report Q4 FY2026 results on Feb 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CRSP stock performed over the past year?
Including dividends, CRSP returned -18.3% over the past year, against +12.0% for the S&P 500.
How many CRSP shares are sold short?
17M shares were sold short at the latest FINRA report, 18.27% of the float, or 13.1 days of average trading volume.
Who are CRISPR Therapeutics's competitors?
Companies most similar to CRISPR Therapeutics by business, industry and size include EDIT, CRBU, DTIL, SGMOQ, CCCC.
See a number that looks wrong?